1. Academic Validation
  2. Silibinin-drived microbiota enrich (R)-2,3-dihydroxy-isovalerate and ameliorate colitis via the GAT-3/RARβ/RORγt axis

Silibinin-drived microbiota enrich (R)-2,3-dihydroxy-isovalerate and ameliorate colitis via the GAT-3/RARβ/RORγt axis

  • ISME J. 2025 Aug 13:wraf175. doi: 10.1093/ismejo/wraf175.
Baofei Yan 1 Xian Zheng 2 Danya Lu 1 Ting Li 1 Xi Chen 3 Zhitao Shao 1 Tingming Fu 1
Affiliations

Affiliations

  • 1 State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Nanjing University of Chinese Medicine, Nanjing 210023, P. R. China.
  • 2 Department of Pharmacy, Affiliated Kunshan Hospital of Jiangsu University, Kunshan 215399, P. R. China.
  • 3 Jiangsu Engineering Research Center for Precision Prevention and Treatment of Digestive and Reproductive System Tumors, Huaian 223003, P. R. China.
Abstract

Microbiota-associated factors are increasingly recognized as significant contributors to the progression of ulcerative colitis, and microbial modulation has emerged as an effective therapy for this condition. The herbal compound silibinin has demonstrated properties that modulate gut microbiota. Herein, we investigated the response of gut microbiota to silibinin in ameliorating colitis, using a mouse model of colitis coupled with Antibiotic exposure. Results indicated that Antibiotic pretreatment negated the benefits of silibinin in mice with colitis. Furthermore, fecal microbiota transplantation involving silibinin-modulated gut microbiota further substantiated the gut microbiota-dependent effects of silibinin. Within the metabolic profiles of silibinin-regulated microbiota, we identified that Alistipes-associated (R)-2,3-dihydroxy-isovalerate exhibited the most pronounced anti-inflammatory effects in vitro and demonstrated protective effects against colitis. Moreover, (R)-2,3-dihydroxy-isovalerate reinstated the protective effects of silibinin in mice with colitis under Antibiotic exposure. These effects were primarily mediated via the targeting of the colonic GABA transporter 3 by (R)-2,3-dihydroxy-isovalerate. We further revealed that the retinoic acid receptor β and the retinoid-related Orphan Nuclear Receptor γt may mediate the impact of silibinin-derived microbiota and (R)-2,3-dihydroxy-isovalerate on colitis. Additionally, the knockdown of colonic GABA transporter 3 diminished the impact of silibinin on the GABA transporter 3/retinoic acid receptor β/retinoid-related Orphan Nuclear Receptor γt axis and colitis. Our findings highlight that (R)-2,3-dihydroxy-isovalerate, enriched from microbiota derived from silibinin, can target the GABA transporter 3/retinoic acid receptor β/retinoid-related Orphan Nuclear Receptor γt axis, which is essential for anti-colitis properties of silibinin-regulated microbiota.

Keywords

(R)-2,3-dihydroxy-isovalerate; GAT-3/RARβ/RORγt axis; gut microbiota; silibinin; ulcerative colitis.

Figures
Products